The discovery and clinical application of PD-1 (Programmed cell death 1), PD-L1 (Programmed cell death ligand 1), and CTLA-4 (Cytotoxic T lymphocyte antigen 4) and their inhibitors have introduced novel therapeutic approaches for combating malignant tumors [3–7]. The gene discussed is CTLA4; the disease is cancer.